Search research articles
Contact Us
Filters
Showing results (91-100 of 149) with videos related to
Page
of 15
Sort By:
Blood
|
June 10, 2006
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma
Massimo Offidani, Laura Corvatta, Maria-Novella Piersantelli, et al.
Haematologica
|
June 22, 2019
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
Vittorio Montefusco, Francesca Gay, Stefano Spada, et al.
Haematologica
|
August 4, 2006
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study
Livio Pagano, Morena Caira, Anna Candoni, et al.
Oncotarget
|
November 18, 2015
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
Carolina Terragna, Daniel Remondini, Marina Martello, et al.
Blood
|
March 19, 2021
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma
Alessandra Larocca, Francesca Bonello, Gianluca Gaidano, et al.
The Journal of Antimicrobial Chemotherapy
|
January 17, 2019
'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study
Maria Ilaria Del Principe, Giulia Dragonetti, Luisa Verga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2010
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial
Antonio Palumbo, Sara Bringhen, Davide Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 20, 2013
Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome
Katia Todoerti, Luca Agnelli, Sonia Fabris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2021
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients
Gian Maria Zaccaria, Luca Bertamini, Maria Teresa Petrucci, et al.
Hemasphere
|
January 25, 2020
Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study
Chiara Cattaneo, Alessandro Busca, Doriana Gramegna, et al.
Page
of 15
Search research articles
Search
Showing results (91-100 of 149) with videos related to
Sort By:
Page
of 15
Blood
|
June 10, 2006
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma
Massimo Offidani, Laura Corvatta, Maria-Novella Piersantelli, et al.
Haematologica
|
June 22, 2019
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
Vittorio Montefusco, Francesca Gay, Stefano Spada, et al.
Haematologica
|
August 4, 2006
The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study
Livio Pagano, Morena Caira, Anna Candoni, et al.
Oncotarget
|
November 18, 2015
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
Carolina Terragna, Daniel Remondini, Marina Martello, et al.
Blood
|
March 19, 2021
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma
Alessandra Larocca, Francesca Bonello, Gianluca Gaidano, et al.
The Journal of Antimicrobial Chemotherapy
|
January 17, 2019
'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study
Maria Ilaria Del Principe, Giulia Dragonetti, Luisa Verga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 14, 2010
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial
Antonio Palumbo, Sara Bringhen, Davide Rossi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 20, 2013
Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome
Katia Todoerti, Luca Agnelli, Sonia Fabris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 30, 2021
Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients
Gian Maria Zaccaria, Luca Bertamini, Maria Teresa Petrucci, et al.
Hemasphere
|
January 25, 2020
Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem Study
Chiara Cattaneo, Alessandro Busca, Doriana Gramegna, et al.
Page
of 15